Dr Fernando Fonseca Guimaraes leads the Translational innate immunotherapy group.

 

Researcher biography

I lead a research program with extensive expertise in immunology, particularly in natural killer (NK) cells, focused on developing innovative approaches for treating hard-to-cure diseases like metastatic cancers. Our mission is to improve patient outcomes and extend lives. My research group is based at the Translational Research Institute (TRI).

My dedication to my field has been recognized through numerous peer-reviwed grants as sole-CI or CIA/Principal Investigator, including a NHMRC ECF Peter Doherty Fellowship, an NHMRC Project Grant, an US DoD, a MRFF EMCR among others. Since 2009, I've amassed an impressive portfolio of 96 publications in renowned journals like Blood, Cell Death Dis, JEM, PNAS, Nat Comms, and Nat Immunol with an H-index = 40. My body of work and contributions have been acknowledged with awards such as the 2019 Researcher of the Year by CCA, 2020 QLD Young Tall Poppy Science, 2020 UQ Frazer Institute's Rising Star, 2022 Frazer Institute's Mentor of the Year, 2023 Translational Research Institute - Connecting with the Clinic among others. Recognized as an international leader in my field, I've been instrumental in identifying novel regulators of our immune functions, and developing NK cell-based immunotherapies.

At present, I am a Group Leader / Principal Research Fellow & Associate Professor with the University of Queensland's Frazer Institute. Here, I lead a high-performing research team with a keen focus on developing and innovating immunotherapy approaches for a spectrum of diseases.